Outset Medical (OM) EBITDA (2019 - 2026)

Outset Medical (OM) has reported EBITDA for 8 consecutive years, with -$15.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBITDA rose 7.05% year-over-year to -$15.7 million in Q2 2026; TTM through Jun 2026 was -$66.0 million, a 16.37% increase from a year earlier, with the FY2025 full-year figure at -$66.7 million, up 41.16% from the prior year.
• EBITDA was -$15.7 million for Q2 2026 at Outset Medical, up from -$16.9 million in the prior quarter.
• Over five years, EBITDA peaked at -$15.7 million in Q2 2026 and troughed at -$45.5 million in Q3 2023.
• A 5-year average of -$30.2 million and a median of -$33.6 million in 2022 frame the typical range for EBITDA.
• Across the five-year window, EBITDA sank 46.19% in 2022 and surged 55.57% in 2025, its largest moves.
• Over 5 years, EBITDA stood at -$39.8 million in 2022, then grew by 6.2% to -$37.4 million in 2023, then jumped by 41.48% to -$21.9 million in 2024, then grew by 19.35% to -$17.6 million in 2025, then advanced by 11.08% to -$15.7 million in 2026.
• The last three EBITDA figures came in at -$15.7 million (Q2 2026), -$16.9 million (Q1 2026), and -$17.6 million (Q4 2025), per Business Quant data.